Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 15 versus DYANAVEL XR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 15 versus DYANAVEL XR 5.
DYANAVEL XR 15 vs DYANAVEL XR 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR contains amphetamine, which is a central nervous system stimulant that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
1-3 capsules orally once daily in the morning. Each capsule contains 15 mg of amphetamine (equivalent to 15 mg dextroamphetamine/amphetamine).
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: amphetamine (d-isomer) 9-11 hours, l-isomer 11-14 hours; allows for once-daily dosing in extended-release formulation
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Renal (80-90% as unchanged drug and metabolites, primarily dehydro-amphetamine); fecal excretion minimal (<5%)
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant